History

Medeor Therapeutics was cofounded in 2012 by Stanford University School of Medicine professors Drs. Samuel Strober, Edgar Engleman, Robert Lowsky; and entrepreneur Chih Ping (CP) Liu, and was originally known as SERC Therapeutics, after the first initial of the four co-founders. Drs. Strober, Engleman, and Lowsky have been collaborating for more than 30 years on translating groundbreaking science into achieving immune tolerance in the clinic for organ and hematopoietic cell transplant patients, such that the lifelong need for immunosuppressive drugs can be safely eliminated. What’s more, they are pioneers in the establishment of persistent mixed chimerism as the key to immune reprogramming without graft versus host disease. Keep scrolling to learn more about the development of Medeor's technology platform and important milestones in the immune tolerance field.

Milestones

2018

The California Institute for Regenerative Medicine awarded Medeor a $11.2M grant to support a Phase 3 clinical trial evaluating the safety and efficacy of MDR-101.

2017

Phase 3 program in HLA-matched living donor kidney transplantation began

2016

Successful technology transfer of Stanford academic manufacturing to Medeor Commercial GMP manufacturer and product comparability demonstrated

2015

Results of the first 38 matched and mismatched kidney transplant patients were published in the American Journal of Transplantation. None had kidney graft loss or graft versus host disease. Successful complete withdrawal of immunosuppressive drugs in 16 of 22 evaluable matched patients without rejection episodes or kidney disease recurrence with up to 5 years follow up.9

2012

Formation of the company as SERC, renamed as Medeor Therapeutics in 2014 to further develop Stanford technology

2012

Results from the Stanford Phase 2 trial of the first 16 patients were published in the American Journal of Transplantation.8

2010

Stanford began a clinical trial designed to generate tolerance through mixed chimerism in patients with HLA mismatched kidney transplant

2008

Stanford published a case report in the New England Journal of Medicine showing that a matched kidney recipient, who was off all anti-rejection drugs for 28 months and counting with no evidence of rejection.7

2005

First human leukocyte antigen (HLA)-matched patient was weaned off all anti-rejection drugs at Stanford.

2004

Stanford began the clinical trial in living matched donor kidney transplant patients designed to generate tolerance through mixed chimerism.

2002

Report in Transplantation that lymphoid irradiation plus donor CD34+ cells induced mixed chimerism in HLA-mismatched kidney transplant recipient.6

2000

Stanford developed the approach to generate tolerance through persistent mixed chimerism after solid organ transplant in humans.5

1993

Dr. Strober’s laboratory developed a completely posttransplant TLI-based conditioning regimen for tolerance induction to combine heart and hematopoietic cell transplants that could be applied to human deceased donor organ transplantation.4

1991

Dr. Strober collaborated with the Stanford heart transplant group to show the potential of total lymphoid irradiation (TLI) in treating heart transplant patients with intractable rejection.3

1978

Dr. Strober and colleagues at Stanford developed the technique for generating immune tolerance with persistent mixed chimerism in mice without evidence of graft versus host disease (GvHD).2

1976

Report published in Science that transplant tolerance can be induced by low-intensity lymphoid irradiation.1


References:
1. Slavin, S., Strober, S., Fuks, Z., and Kaplan, H.S. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science, 193:1252-1254, 1976.
2. Slavin, S., Fuks, Z., Kaplan, H.S., and Strober, S. Transplantation of allogeneic bone marrow without graft vs. host disease using total lymphoid irradiation. J. Exp. Med., 147:963-972, 1978. 
3. Hunt, S.A., Strober, S., Hoppe, R.T., and Stinson, E.B. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J. Heart Transplant. 10(2):211-216, 1991.
4. Woodley, S.L., Gurley, K.E., Hoffmann, S.L., Nicolls, M.R., Hagberg, R., Clayberger, C., Holm, B., Wang, X., Hall, B.M., and Strober. S. Induction of tolerance to heart allografts in rats using posttransplant TLI and anti-T cell antibodies. Transplantation, 56:1443-1447, 1993.
5.
Strober, S. Benike, C., Krishnaswamy, S., Engleman, E.G., Grumet, F.K. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: Studies of chimerism and anti-donor reactivity. Transplantation. 69:1549-1554, 2000
6. Millan, M.T., Shizuru, J.A., Hoffmann, P., Dejbakhsh-Jones, J.D., Scandling, J.D., Grumet, F.C., Tan, J.C., Salvatierra, O., and Strober, S. Mixed Chimerism without graft versus host disease after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 73:1386-1391, 2002.
7. Scandling, J.D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M.T., Shizuru, J.A., Hoppe, R.T., Lowsky, R., Engleman, E.G., and Strober, S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. New Engl. J. Med 358(4):362-368 2008.
8. Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M.T., Shizuru, J., Lowsky, R., Engleman, E.G., and Strober, S. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. AJT. 12 (5):1133-1145 2012.
9. Scandling JD, Busque S, Shizuru JA, Lowsky R, Hoppe R, Dejbakhsh-Jones S, Jensen K, Shori A, Strober JA, Lavori P, Turnbull BB, Engleman EG, Strober S. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after kidney and hematopoietic cell transplantation. AJT. 15 (3): 695-704. 2015.